Cavitation Technologies sits at the intersection of PFAS regulation, 40+ patents, a $40–42M LOI and a 2026 commercialization path. Analysts say that catalyst stack could re-rate the stock dramatically if execution lands.
Cavitation Technologies attracts attention as investors connect water remediation, patent protection and a possible microcap re-rating.
Base, Arbitrum and Optimism collectively post double-digit growth in the last 30 days.
NVIDIA, Meta and Microsoft accounted for nearly 60% of the index's daily gain.
Investors are rotating into water remediation and infrastructure plays amid regulatory tailwinds.
BlackRock's IBIT and Fidelity's FBTC continue to dominate institutional flows.
Sub-$50M companies in clean-tech and biotech are outperforming the broader Russell 2000.
Analyst consensus moves higher again as AI infrastructure spend continues to accelerate.
From LOI letters to proof-of-funds confirmations — what to look for before the crowd does.
A breakdown of the PFAS, water-tech, LOI and commercialization catalysts behind one of the most-watched microcap stories of the month.
Why water scarcity, PFAS remediation and patented cavitation technology are quietly attracting investor attention.